- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03302897
Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers
April 9, 2019 updated by: IDRI
A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects
The purpose of this study is to compare the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of leprosy.
Two dose levels of the vaccine will be evaluated.
Study Overview
Detailed Description
The purpose of this study is to compare the safety, tolerability, and immunogenicity of the LEP-F1 + GLA-SE vaccine.
The vaccine consists of the recombinant four-antigen Mycobacterium leprae antigen LEP-F1 in combination with the adjuvant formulation GLA-SE (Glucopyranosyl Lipid A - Stable Emulsion) and is being developed for the prevention of leprosy disease.
This is a first-in-human study and will be conducted in healthy adult subjects.
Two dose levels of the vaccine (2 μg LEP-F1 + 5 μg GLA-SE and 10 μg LEP-F1 + 5 μg GLA-SE) will be given by intramuscular administration on study Days 0, 28, and 56.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53704
- Covance Clinical Research Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females 18 years to 55 years of age.
- Must be in good general health as confirmed by a medical history and physical exam.
- Female subjects of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on the day of each study vaccination, must not be breast-feeding, and are required to use one of the following methods of contraception from enrollment (Day 0) in study until 30 days after last injection (only if in sexual relationships with men): hormonal (e.g. oral, transdermal, intravaginal, implant, or injection); double barrier (i.e., condom, diaphragm, or cervical cap with spermicide); intrauterine device (IUD) or system (IUS); vasectomized partner (6 months minimum); or abstinence; bilateral tubal ligation (if no conception post-procedure); tubal occlusion; or bilateral salpingectomy. These precautions are necessary due to unknown effects that LEP-F1 + GLA-SE might cause in a fetus or newborn infant. Women are considered non-child-bearing potential if they are post-menopausal (defined as at least 12 months spontaneous amenorrhea and confirmed with FSH > 40 mIU/ml) or have had documented hysterectomy and/or oophorectomy.
- The following screening laboratory values must be within the normal ranges or not clinically significant as determined by the Investigator and approved by the Medical Monitor: sodium, potassium, BUN, ALT, AST, total bilirubin, alkaline phosphatase, creatinine, fasting glucose, total WBC count, hemoglobin, and platelet count. Abnormal results may be repeated once for confirmation at Investigator discretion.
- The following serology tests must be negative: HIV 1/2 antibody, hepatitis B surface antigen (HBsAg), QuantiFERON®-TB Gold (QFT), and hepatitis C virus (HCV) antibody.
- Negative test for recreational drugs and alcohol per Clinical Research Unit standards.
- Normal or not clinically significant urinalysis as determined by the study clinician or designee. Abnormal results may be repeated at Investigator discretion.
- Must be capable of completing a study memory aid in English.
- Must give informed consent, be able and willing to make all evaluation visits, be reachable by telephone or personal contact by the study site personnel, and have a permanent address.
Exclusion Criteria:
- History of infection with M. leprae or previous exposure to M. leprae vaccines or experimental products containing GLA-SE.
- History of BCG vaccination.
- History of active or documented latent TB.
- History of previous infection with other non-tuberculous mycobacteria.
- Travel to or residence in India, Brazil, or Indonesia for more than 6 months.
- Participation in another experimental protocol and/or receipt of any investigational products within the past 3 months prior to Screening.
- Treatment with immunosuppressive drugs (e.g., oral or injected steroids, such as prednisone; high dose inhaled steroids) or cytotoxic therapies (e.g., chemotherapy drugs or radiation) in the past 6 months prior to Screening.
- Received a blood transfusion within past 3 months prior to Screening.
- Donated blood products (platelets, whole blood, plasma, etc.) within past one month prior to Screening.
- Received any vaccine within past 1 month prior to Screening or have any planned immunizations while on study, with the exception of seasonal influenza vaccine which can be given after 1 month post the third study injection (Day 84).
- History of autoimmune disease or other causes of immunosuppressive states.
- History of any other acute or chronic illness (including cardiovascular, pulmonary, neurological, hepatic, rheumatic, hematological, metabolic or renal disorders, uncontrolled hypertension), or use of medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.
- Rash, tattoos, or any other dermatological condition that could adversely affect the vaccine injection site or interfere with its evaluation.
- BMI ≥ 32.
- Hypertension (systolic > 150 or diastolic > 95) at screening and Day 0.
- History of significant psychiatric illness with current use of medication.
- Known or suspected alcohol or drug abuse within the past 6 months prior to Screening.
- Chronic tobacco user (> 20 pack years).
- Subjects with a history of previous anaphylaxis or severe allergic reaction to vaccines or unknown allergens.
- Subjects who are unlikely to cooperate with the requirements of the study protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2 μg LEP-F1 + 5 μg GLA-SE
Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56.
Low dose of antigen.
|
Investigational vaccine
|
Experimental: 10 μg LEP-F1 + 5 μg GLA-SE
Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56.
Higher dose of antigen.
|
Investigational vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events
Time Frame: 421 days
|
Solicited and unsolicited adverse events will be recorded for 28 days following each study injection; serious adverse events and adverse events of special interest will be recorded for the duration of the study.
|
421 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity (IgG antibody and T cell responses to LEP-F1)
Time Frame: Days 0, 35, and 63
|
Immunogenicity will be evaluated by measuring humoral and cellular responses to LEP-F1 + GLA-SE at specified timepoints.
|
Days 0, 35, and 63
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Corey Casper, MD, MPH, IDRI
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 2, 2017
Primary Completion (Actual)
March 5, 2019
Study Completion (Actual)
March 5, 2019
Study Registration Dates
First Submitted
October 2, 2017
First Submitted That Met QC Criteria
October 2, 2017
First Posted (Actual)
October 5, 2017
Study Record Updates
Last Update Posted (Actual)
April 11, 2019
Last Update Submitted That Met QC Criteria
April 9, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IDRI-LEPVPX-118
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leprosy
-
Paul SaundersonCompletedLepromatous Leprosy | Borderline Lepromatous LeprosyPhilippines
-
Janssen Research & Development, LLCCompletedLeprosy, MultibacillaryBrazil
-
Federal University of UberlandiaUnknownLeprosy NeuropathyBrazil
-
Eijkman Oxford Clinical Research Unit, IndonesiaLondon School of Hygiene and Tropical Medicine; Radboud University Medical... and other collaboratorsRecruitingLeprosy | Leprosy, Multibacillary | Neglected Tropical DiseasesIndonesia
-
Yunia IrawatiCompletedParalytic Lagophthalmos | Leprosy--PatientsIndonesia
-
Yohanes Firmansyah, dr, MH, MMTarumanagara UniversityCompletedCM-MSC ; Stem Cell ; Trophic Ulcer ; Leprosy ; Morbun Hansen; SecretomIndonesia
-
University of Sao PauloCristália Produtos Químicos Farmacêuticos Ltda.Active, not recruitingLeprosy | Pain, Neuropathic | Leprosy Neuropathy | AmitriptylineBrazil
-
Institute of Tropical Medicine, BelgiumDamien FoundationCompleted
-
London School of Hygiene and Tropical MedicineArmauer Hansen Research Institute, Ethiopia; Alert Hospital, Ethiopia; Homes...Completed
Clinical Trials on LEP-F1 + GLA-SE
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Oswaldo Cruz InstituteNot yet recruiting
-
IDRIRockefeller UniversityCompleted
-
U.S. Army Medical Research and Development CommandUnited States Agency for International Development (USAID); IDRICompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
Rockefeller UniversityImmune Design; IDRI CorporationCompleted
-
IDRIBill and Melinda Gates FoundationCompletedVisceral LeishmaniasisUnited States
-
Access to Advanced Health Institute (AAHI)National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...Completed
-
Quratis Inc.UnknownTuberculosisKorea, Republic of
-
Quratis Inc.IDRIUnknownTuberculosisKorea, Republic of
-
Immune DesignCompletedMerkel Cell CarcinomaUnited States